Insider Trading activities of Arrowhead Pharmaceuticals, Inc. (ARWR)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Arrowhead Pharmaceuticals, Inc. (ARWR) since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Arrowhead Pharmaceuticals, Inc. since year 2005. Table 2 shows the detailed insider transactions of Arrowhead Pharmaceuticals, Inc. since 2005. The reporting company's ticker symbol is ARWR. The reporting company's CIK number is 879407.
The total value of stock buying since 2005 is $680,600.
The total value of stock sales since 2005 is $45,209,609.
The total value of stock option exercises since 2005 is $3,637,660.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Arrowhead Pharmaceuticals, Inc. (ARWR).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2019-06 0 $0 17,756 $490,243 0 $0
2019-05 0 $0 57,071 $1,341,962 84,448 $285,796
2019-04 0 $0 50,000 $965,000 0 $0
2019-03 0 $0 42,500 $849,574 42,500 $85,424
2019-02 0 $0 753,084 $13,336,876 483,834 $1,557,606
2019-01 0 $0 446,374 $6,226,920 12,666 $55,857
2018-12 0 $0 183,000 $2,555,100 0 $0
2018-11 0 $0 84,500 $1,232,195 0 $0
2018-10 0 $0 131,137 $1,769,038 131,137 $729,515
2018-09 0 $0 109,834 $1,814,576 45,000 $165,825
2018-08 0 $0 100,000 $1,445,000 0 $0
2018-06 0 $0 20,000 $280,200 20,000 $40,199
2018-05 0 $0 14,000 $154,000 14,000 $28,138
2018-04 0 $0 25,000 $165,750 0 $0
2018-03 0 $0 366,000 $2,715,000 20,000 $40,199
2018-01 0 $0 20,000 $73,800 0 $0
2016-10 0 $0 12,000 $80,640 0 $0
2016-08 0 $0 20,000 $160,000 20,000 $40,198
2016-06 0 $0 0 $0 15,772 $80,279
2015-12 0 $0 23,347 $143,117 0 $0
2015-01 0 $0 15,000 $120,105 15,000 $30,149
2014-10 16,000 $101,120 2,500 $36,747 2,500 $12,975
2014-09 0 $0 17,000 $255,825 17,000 $34,529
2014-08 0 $0 45,000 $630,380 45,000 $253,849
2014-06 0 $0 22,000 $314,996 22,000 $52,909
2014-02 0 $0 19,148 $350,583 21,000 $82,159
2014-01 0 $0 15,000 $154,290 15,000 $62,054
2013-10 2,300 $14,808 0 $0 0 $0
2010-08 35,000 $31,150 0 $0 0 $0
2008-08 164,000 $0 0 $0 0 $0
2007-12 0 $0 1,000 $3,860 0 $0
2007-11 0 $0 1,000 $3,910 0 $0
2007-10 0 $0 1,000 $5,000 0 $0
2007-09 0 $0 1,000 $5,040 0 $0
2007-08 0 $0 1,000 $5,440 0 $0
2007-07 0 $0 1,000 $4,880 0 $0
2007-06 0 $0 1,000 $7,210 0 $0
2007-05 0 $0 1,000 $7,000 0 $0
2007-04 0 $0 1,000 $4,576 0 $0
2007-03 0 $0 1,449,572 $5,530,756 0 $0
2007-02 0 $0 1,000 $4,010 0 $0
2007-01 2,000 $8,352 1,000 $4,010 0 $0
2006-08 102,250 $498,980 0 $0 0 $0
2005-05 10,000 $26,190 0 $0 0 $0
2005-04 0 $0 600,000 $1,962,000 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Arrowhead Pharmaceuticals, Inc. insiders (ARWR)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2019-06-26 Ferrari Mauro (Director) Sale 17,756 27.61 490,243
2019-05-31 Myszkowski Kenneth Allen (Chief Financial Officer) Option Ex 35,000 4.89 171,324
2019-05-28 O'brien Patrick (General Counsel) Sale 30,000 24.88 746,400
2019-05-24 Anzalone Christopher Richard (Chief Executive Officer) Option Ex 49,448 2.31 114,472
2019-05-21 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 27,071 22.00 595,562
2019-04-03 Anzalone Christopher Richard (Chief Executive Officer) Sale 50,000 19.30 965,000
2019-03-01 Given Bruce D (Chief Operating Officer) Sale 42,500 19.99 849,574
2019-03-01 Given Bruce D (Chief Operating Officer) Option Ex 42,500 2.01 85,424
2019-02-26 Given Douglas B (Director) Sale 195,000 19.25 3,753,750
2019-02-26 Given Douglas B (Director) Option Ex 195,000 3.69 719,160
2019-02-25 Given Bruce D (Chief Operating Officer) Sale 42,500 18.98 806,650
2019-02-25 Given Bruce D (Chief Operating Officer) Option Ex 42,500 2.01 85,424
2019-02-22 Given Douglas B (Director) Sale 9,000 18.05 162,450
2019-02-19 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 8,000 18.00 144,000
2019-02-19 Myszkowski Kenneth Allen (Chief Financial Officer) Option Ex 8,000 5.20 41,600
2019-02-19 Given Bruce D (Chief Operating Officer) Sale 42,500 17.98 764,150
2019-02-19 Given Bruce D (Chief Operating Officer) Option Ex 42,500 2.01 85,424
2019-02-15 Given Bruce D (Chief Operating Officer) Sale 26,250 17.67 463,837
2019-02-12 Given Bruce D (Chief Operating Officer) Sale 42,500 17.06 725,050
2019-02-12 Given Bruce D (Chief Operating Officer) Option Ex 42,500 2.01 85,424
2019-02-11 Given Bruce D (Chief Operating Officer) Sale 154,167 16.07 2,477,463
2019-02-11 Given Bruce D (Chief Operating Officer) Option Ex 11,667 2.62 30,567
2019-02-08 Given Bruce D (Chief Operating Officer) Sale 46,167 15.34 708,201
2019-02-08 Given Bruce D (Chief Operating Officer) Option Ex 11,667 2.62 30,567
2019-02-05 Given Bruce D (Chief Operating Officer) Sale 22,500 14.48 325,800
2019-02-01 Given Bruce D (Chief Operating Officer) Sale 28,500 13.85 394,725
2019-01-23 Given Bruce D (Chief Operating Officer) Sale 17,500 13.15 230,125
2019-01-22 Given Bruce D (Chief Operating Officer) Sale 152,000 13.59 2,065,680
2019-01-22 Given Douglas B (Director) Sale 3,000 13.58 40,740
2019-01-18 O'brien Patrick (General Counsel) Sale 72,000 14.43 1,038,960
2019-01-17 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 81,875 14.55 1,191,281
2019-01-14 Li Zhen (Snr. VP, Chem and Non-Clin Dev) Sale 40,500 14.34 580,770
2019-01-14 Given Bruce D (Chief Operating Officer) Sale 42,666 14.40 614,390
2019-01-14 Given Bruce D (Chief Operating Officer) Option Ex 12,666 4.41 55,857
2019-01-11 Waddill William D. (Director) Sale 8,500 14.77 125,545
2019-01-02 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 8,333 11.98 99,829
2019-01-02 Given Bruce D (Chief Operating Officer) Sale 20,000 11.98 239,600
2018-12-27 Given Douglas B (Director) Sale 3,000 12.00 36,000
2018-12-19 Anzalone Christopher Richard (Chief Executive Officer) Sale 90,000 13.92 1,252,800
2018-12-12 Anzalone Christopher Richard (Chief Executive Officer) Sale 90,000 14.07 1,266,300
2018-11-23 Given Douglas B (Director) Sale 3,000 12.74 38,220
2018-11-09 Anzalone Christopher Richard (Chief Executive Officer) Sale 81,500 14.65 1,193,975
2018-10-19 Leone Peter Brian (VP, Strategic Bus. Initiatives) Sale 131,137 13.49 1,769,038
2018-10-19 Leone Peter Brian (VP, Strategic Bus. Initiatives) Option Ex 131,137 5.56 729,515
2018-09-06 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 45,000 19.50 877,725
2018-09-06 Myszkowski Kenneth Allen (Chief Financial Officer) Option Ex 45,000 3.69 165,825
2018-09-04 Anzalone Christopher Richard (Chief Executive Officer) Sale 64,834 14.45 936,851
2018-08-31 Anzalone Christopher Richard (Chief Executive Officer) Sale 100,000 14.45 1,445,000
2018-06-19 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 20,000 14.01 280,200
2018-06-19 Myszkowski Kenneth Allen (Chief Financial Officer) Option Ex 20,000 2.01 40,199
2018-05-31 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 12,600 11.00 138,600
2018-05-31 Myszkowski Kenneth Allen (Chief Financial Officer) Option Ex 12,600 2.01 25,325
2018-05-30 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 1,400 11.00 15,400
2018-05-30 Myszkowski Kenneth Allen (Chief Financial Officer) Option Ex 1,400 2.01 2,813
2018-04-24 Given Douglas B (Director) Sale 25,000 6.63 165,750
2018-03-27 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 20,000 8.00 160,000
2018-03-27 Myszkowski Kenneth Allen (Chief Financial Officer) Option Ex 20,000 2.01 40,199
2018-03-16 Anzalone Christopher Richard (Chief Executive Officer) Sale 26,000 7.40 192,400
2018-03-15 Anzalone Christopher Richard (Chief Executive Officer) Sale 100,000 7.41 741,000
2018-03-14 Anzalone Christopher Richard (Chief Executive Officer) Sale 100,000 7.44 744,000
2018-03-13 Anzalone Christopher Richard (Chief Executive Officer) Sale 100,000 7.43 743,000
2018-03-05 Given Bruce D (Chief Operating Officer) Sale 20,000 6.73 134,600
2018-01-01 Given Bruce D (Chief Operating Officer) Sale 20,000 3.69 73,800
2016-10-14 Given Douglas B (Director) Sale 12,000 6.72 80,640
2016-08-23 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 6,900 8.00 55,200
2016-08-23 Myszkowski Kenneth Allen (Chief Financial Officer) Option Ex 6,900 2.01 13,868
2016-08-22 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 13,100 8.00 104,800
2016-08-22 Myszkowski Kenneth Allen (Chief Financial Officer) Option Ex 13,100 2.01 26,330
2016-06-30 Anzalone Christopher Richard (Chief Executive Officer) Option Ex 15,772 5.09 80,279
2015-12-30 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 23,347 6.13 143,117
2015-01-05 Lewis David L. (Chief Scientific Officer) Sale 15,000 8.01 120,105
2015-01-05 Lewis David L. (Chief Scientific Officer) Option Ex 15,000 2.01 30,149
2014-10-15 Anzalone Christopher Richard (President and CEO) Buy 16,000 6.32 101,120
2014-10-01 Mckenney Charles (Director) Sale 2,500 14.70 36,747
2014-10-01 Mckenney Charles (Director) Option Ex 2,500 5.19 12,975
2014-09-30 Lewis David L. (Chief Scientific Officer) Sale 15,000 15.02 225,345
2014-09-30 Lewis David L. (Chief Scientific Officer) Option Ex 15,000 2.01 30,149
2014-09-26 Given Douglas B (Director) Sale 2,000 15.24 30,480
2014-09-26 Given Douglas B (Director) Option Ex 2,000 2.19 4,380
2014-08-15 Myszkowski Kenneth Allen (CFO) Sale 40,000 14.02 560,880
2014-08-15 Myszkowski Kenneth Allen (CFO) Option Ex 40,000 6.09 243,800
2014-08-15 Given Douglas B (Director) Sale 5,000 13.90 69,500
2014-08-15 Given Douglas B (Director) Option Ex 5,000 2.01 10,049
2014-06-09 Mckenney Charles (Director) Sale 22,000 14.32 314,996
2014-06-09 Mckenney Charles (Director) Option Ex 22,000 2.40 52,909
2014-02-12 Myszkowski Kenneth Allen (CFO) Sale 16,000 18.77 300,288
2014-02-12 Myszkowski Kenneth Allen (CFO) Option Ex 16,000 2.01 32,159
2014-02-07 Frykman Edward W (Director) Sale 3,148 15.98 50,295
2014-02-07 Frykman Edward W (Director) Option Ex 5,000 10.00 50,000
2014-01-02 Lewis David L. (Chief Scientific Officer) Sale 15,000 10.29 154,290
2014-01-02 Lewis David L. (Chief Scientific Officer) Option Ex 15,000 4.14 62,054
2013-10-28 Ferrari Mauro (Director) Buy 400 7.62 3,047
2013-10-09 Ferrari Mauro (Director) Buy 1,900 6.19 11,761
2010-08-31 Anzalone Christopher Richard (President and CEO) Buy 10,000 .89 8,900
2010-08-27 Myszkowski Kenneth Allen (CFO) Buy 15,000 .89 13,350
2010-08-27 Anzalone Christopher Richard (President and CEO) Buy 10,000 .89 8,900
2008-08-22 Anzalone Christopher Richard (President and CEO) Buy 164,000 .00 0
2007-12-05 Mckenney Charles (Director) Sale 1,000 3.86 3,860
2007-11-05 Mckenney Charles (Director) Sale 1,000 3.91 3,910
2007-10-05 Mckenney Charles (Director) Sale 1,000 5.00 5,000
2007-09-05 Mckenney Charles (Director) Sale 1,000 5.04 5,040
2007-08-06 Mckenney Charles (Director) Sale 1,000 5.44 5,440
2007-07-05 Mckenney Charles (Director) Sale 1,000 4.88 4,880
2007-06-05 Mckenney Charles (Director) Sale 1,000 7.21 7,210
2007-05-07 Mckenney Charles (Director) Sale 1,000 7.00 7,000
2007-04-05 Mckenney Charles (Director) Sale 1,000 4.58 4,576
2007-03-21 Knott David M (10% Owner) Sale 1,410,950 3.81 5,374,308
2007-03-19 Knott David M (10% Owner) Sale 9,940 3.93 39,064
2007-03-16 Knott David M (10% Owner) Sale 27,682 4.11 113,634
2007-03-05 Mckenney Charles (Director) Sale 1,000 3.75 3,750
2007-02-20 Mckenney Charles (Director) Sale 500 3.98 1,990
2007-02-05 Mckenney Charles (Director) Sale 500 4.04 2,020
2007-01-22 Mckenney Charles (Director) Sale 500 4.01 2,005
2007-01-16 Mckenney Charles (Director) Sale 500 4.01 2,005
2007-01-10 Kingsley Joseph Theodore Iii (Interim President & CFO) Buy 2,000 4.18 8,352
2006-08-16 Knott David M Buy 102,250 4.88 498,980
2005-05-19 Kingsley Joseph Theodore Iii (Chief Financial Officer) Buy 10,000 2.62 26,190
2005-04-21 Ching Marshall Robert (10% Owner) Sale 600,000 3.27 1,962,000

Insider trading activities including stock purchases, stock sales, and option exercises of ARWR listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Arrowhead Pharmaceuticals, Inc. (symbol ARWR, CIK number 879407) see the Securities and Exchange Commission (SEC) website.